Brokers Issue Forecasts for REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings per share of $38.93 for the year. Cantor Fitzgerald currently has a "Neutral" rating and a $1,015.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $37.72 per share.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price objective for the company. Leerink Partners reiterated a "market perform" rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Finally, Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $2.15 during midday trading on Wednesday, reaching $685.65. The company had a trading volume of 320,271 shares, compared to its average volume of 848,272. Regeneron Pharmaceuticals has a 1 year low of $666.25 and a 1 year high of $1,211.20. The business's 50-day simple moving average is $733.06 and its 200 day simple moving average is $943.95. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $75.35 billion, a P/E ratio of 16.97, a P/E/G ratio of 1.61 and a beta of 0.10.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $49,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.